Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia
NCT ID: NCT00607256
Last Updated: 2019-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
500 participants
INTERVENTIONAL
2007-10-20
2009-05-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Open Label
[S,S]-reboxetine
S\_S reboxetine dosed daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
[S,S]-reboxetine
S\_S reboxetine dosed daily.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Orangevale, California, United States
Pfizer Investigational Site
Santa Ana, California, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Jacksonville, Florida, United States
Pfizer Investigational Site
Ocala, Florida, United States
Pfizer Investigational Site
Ocala, Florida, United States
Pfizer Investigational Site
West Palm Beach, Florida, United States
Pfizer Investigational Site
Moline, Illinois, United States
Pfizer Investigational Site
Prairie Village, Kansas, United States
Pfizer Investigational Site
Lexington, Kentucky, United States
Pfizer Investigational Site
Jefferson City, Missouri, United States
Pfizer Investigational Site
St Louis, Missouri, United States
Pfizer Investigational Site
Kenilworth, New Jersey, United States
Pfizer Investigational Site
Rochester, New York, United States
Pfizer Investigational Site
Staten Island, New York, United States
Pfizer Investigational Site
Cary, North Carolina, United States
Pfizer Investigational Site
Minot, North Dakota, United States
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Marion, Ohio, United States
Pfizer Investigational Site
Medford, Oregon, United States
Pfizer Investigational Site
Bethlehem, Pennsylvania, United States
Pfizer Investigational Site
Duncansville, Pennsylvania, United States
Pfizer Investigational Site
Cranston, Rhode Island, United States
Pfizer Investigational Site
Cumberland, Rhode Island, United States
Pfizer Investigational Site
Lincoln, Rhode Island, United States
Pfizer Investigational Site
Warwick, Rhode Island, United States
Pfizer Investigational Site
Anderson, South Carolina, United States
Pfizer Investigational Site
Charleston, South Carolina, United States
Pfizer Investigational Site
Greer, South Carolina, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Lake Jackson, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Salt Lake City, Utah, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Virginia Beach, Virginia, United States
Pfizer Investigational Site
Spokane, Washington, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Pfizer Investigational Site
Brussels, , Belgium
Pfizer Investigational Site
Pellenberg, , Belgium
Pfizer Investigational Site
Kelowna, British Columbia, Canada
Pfizer Investigational Site
Moncton, New Brunswick, Canada
Pfizer Investigational Site
Pointe-Claire, Quebec, Canada
Pfizer Investigational Site
Sherbrooke, Quebec, Canada
Pfizer Investigational Site
Hlučín, , Czechia
Pfizer Investigational Site
Pardubice, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Zlín, , Czechia
Pfizer Investigational Site
Lille, Cedex, France
Pfizer Investigational Site
Nice, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Eichstätt, , Germany
Pfizer Investigational Site
Göppingen, , Germany
Pfizer Investigational Site
Hamburg, , Germany
Pfizer Investigational Site
Mannheim, , Germany
Pfizer Investigational Site
München, , Germany
Pfizer Investigational Site
Wiesbaden, , Germany
Pfizer Investigational Site
Breda, , Netherlands
Pfizer Investigational Site
Emmen, , Netherlands
Pfizer Investigational Site
Leeuwarden, , Netherlands
Pfizer Investigational Site
Boksburg, Gauteng, South Africa
Pfizer Investigational Site
Pretoria, Gauteng, South Africa
Pfizer Investigational Site
Panorama, Western Cape, South Africa
Pfizer Investigational Site
Parow, Western Cape, South Africa
Pfizer Investigational Site
Suwon, Kyeongki-do, South Korea
Pfizer Investigational Site
Gwangju, , South Korea
Pfizer Investigational Site
Gothenburg, , Sweden
Pfizer Investigational Site
Mölndal, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Cambridge, , United Kingdom
Pfizer Investigational Site
Colchester, , United Kingdom
Pfizer Investigational Site
Derby, , United Kingdom
Pfizer Investigational Site
Dudley, West Midlands, , United Kingdom
Pfizer Investigational Site
Greenock, , United Kingdom
Pfizer Investigational Site
Paisley, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6061046
Identifier Type: -
Identifier Source: org_study_id